Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737

Journal of Clinical Investigation

Volumn 117, Issue 1, 2007, Pages 112-121

  Moore, Victoria Del Gaizo ^a   Brown, Jennifer R ^a   Certo, Michael ^a   Love, Tara M ^a   Novina, Carl D ^a   Letai, Anthony ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BIM PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MCL 1;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL MEMBRANE PERMEABILITY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; GENE ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOCHONDRION; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENSITIVITY ANALYSIS; SEQUENCE HOMOLOGY;

ANTINEOPLASTIC AGENTS; APOPTOSIS REGULATORY PROTEINS; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; BIPHENYL COMPOUNDS; CELL DEATH; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MEMBRANE PROTEINS; NEOPLASM STAGING; NITROPHENOLS; PIPERAZINES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES; TUMOR CELLS, CULTURED;

EID: 33845994359     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI28281     Document Type: Article

References (40)

1. Cory, S., and Adams, J.M. 2002. The Bcl2 family: regulators of the cellular life-or-death switch. Nat. Rev. Cancer. 2:647-656.
2. Danial, N.N., and Korsmeyer, S.J. 2004. Cell death: critical control points. Cell. 116:205-219.
3. Puthalakath, H., and Strasser, A. 2002. Keeping killers on a tight leash: transcriptional and posttranslational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ. 9:505-512.
4. Kelekar, A., and Thompson, C.B. 1998. Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol. 8:324-330.
5. Boyd, J.M., et al. 1995. Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins. Oncogene. 11:1921-1928.
6. Zong, W.X., Lindsten, T., Ross, A.J., MacGregor, G.R., and Thompson, C.B. 2001. BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev. 15:1481-1486.
7. Wei, M.C., et al. 2001. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science. 292:727-730.
8. Letai, A., et al. 2002. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2:183-192.
9. Kuwana, T., et al. 2005. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol. Cell. 17:525-535.
10. Green, D.R., and Kroemer, G. 2004. The pathophysiology of mitochondrial cell death. Science. 305:626-629.
11. Wang, X. 2001. The expanding role of mitochondria in apoptosis. Genes Dev. 15:2922-2933.
12. Cheng, E.H., Levine, B., Boise, L.H., Thompson, C.B., and Hardwick, J.M. 1996. Bax-independent inhibition of apoptosis by Bcl-XL. Nature. 379:554-556.
13. Cheng, E.H., et al. 2001. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol. Cell. 8:705-711.
14. Certo, M., et al. 2006. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 9:351-365.
15. Oltersdorf, T., et al. 2005. An inhibitor of Bcl-2 family proteins induces regression of solid tumors. Nature. 435:677-681.
16. Bouillet, P., et al. 1999. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science. 286:1735-1738.
17. Opferman, J.T., et al. 2003. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature. 426:671-676.
18. Han, J., et al. 2004. Degradation of Mcl-1 by granzyme B: implications for Bim-mediated mitochondrial apoptotic events. J. Biol. Chem. 279:22020-22029.
19. Han, J., Goldstein, L.A., Gastman, B.R., and Rabinowich, H. 2006. Interrelated roles for Mcl-1 and Bim in regulation of TRAIL-mediated mitochondrial apoptosis. J. Biol. Chem. 281:10153-10163.
20. Kitada, S., et al. 1998. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood. 91:3379-3389.
21. Saxena, A., et al. 2004. Mcl-1 and Bcl-2/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia. Am. J. Hematol. 75:22-33.
22. Gomez-Bougie, P., Oliver, L., Le Gouill, S., Bataille, R., and Amiot, M. 2005. Melphalan-induced apoptosis in multiple myeloma cells is associated with a cleavage of Mcl-1 and Bim and a decrease in the Mcl-1/Bim complex. Oncogene. 24:8076-8079.
23. Wei, M.C., et al. 2000. tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev. 14:2060-2071.
24. Alves, N.L., et al. 2006. The Noxa/Mcl-1 axis regulates susceptibility to apoptosis under glucose limitation in dividing T cells. Immunity. 24:703-716.
25. Zhu, Y., et al. 2004. Constitutive association of the proapoptotic protein Bim with Bcl-2-related proteins on mitochondria in T cells. Proc. Natl. Acad. Sci. U. S. A. 101:7681-7686.
26. Marani, M., Tenev, T., Hancock, D., Downward, J., and Lemoine, N.R. 2002. Identification of novel isoforms of the BH3 domain protein Bim which directly activate Bax to trigger apoptosis. Mol. Cell. Biol. 22:3577-3589.
27. Yamaguchi, H., and Wang, H.G. 2002. Bcl-XL protects BimEL-induced Bax conformational change and cytochrome C release independent of interacting with Bax or BimEL. J. Biol. Chem. 277:41604-41612.
28. Chen, L., et al. 2005. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol. Cell. 17:393-403.
29. Derenne, S., et al. 2002. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood. 100:194-199.
30. Green, D.R., and Evan, G.I. 2002. A matter of life and death. Cancer Cell. 1:19-30.
31. Hahn, W.C., and Weinberg, R.A. 2002. Modelling the molecular circuitry of cancer. Nat. Rev. Cancer. 2:331-341.
32. Calin, G.A., et al. 2005. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med. 353:1793-1801.
33. O'Brien, S.M., et al. 2005. Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J. Clin. Oncol. 23:7697-7702.
34. Puthalakath, H., Huang, D.C., O'Reilly, L.A., King, S.M., and Strasser, A. 1999. The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol. Cell. 3:287-296.
35. Letai, A., Beard, C., Sorcinelli, M., and Korsmeyer, S.J. 2004. Anti-apoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell. 6:241-249.
36. Vaux, D.L., Cory, S., and Adams, J.M. 1988. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c- myc to immortalize pre-B cells. Nature. 335:440-442.
37. McDonnell, T.J., et al. 1989. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell. 57:79-88.
38. Dohner, H., et al. 2000. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 343:1910-1916.
39. Rassenti, L.Z., et al. 2004. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N. Engl. J. Med. 351:893-901.
40. Ernst, P., Mabon, M., Davidson, A.J., Zon, L.I., and Korsmeyer, S.J. 2004. An Mll-dependent Hox program drives hematopoietic progenitor expansion. Curr. Biol. 14:2063-2069.